| ELL2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | ELL2, elongation factor for RNA polymerase II 2, MRCCAT1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 601874 MGI: 2183438 HomoloGene: 8094 GeneCards: ELL2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Elongation factor for RNA polymerase II 2 is a protein that in humans is encoded by the ELL2 gene. [5]
The encoded protein is a component of the superelongation complex (SEC) and drives immunoglobulin synthesis in plasma cells. Sequence variation in ELL2 has been associated with multiple myeloma and altered immunoglobulin levels.
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000118985 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000001542 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Entrez Gene: Elongation factor for RNA polymerase II 2". Retrieved 2018-08-24.
Further reading
- Martincic K, Alkan SA, Cheatle A, Borghesi L, Milcarek C (October 2009). "Transcription elongation factor ELL2 directs immunoglobulin secretion in plasma cells by stimulating altered RNA processing". Nat. Immunol. 10 (10): 1102–9. doi:10.1038/ni.1786. PMC 2771556. PMID 19749764.
- Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR (2010). "Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score". Mol. Med. 16 (7–8): 247–53. doi:10.2119/molmed.2009.00159. PMC 2896464. PMID 20379614.
- Liu M, Hsu J, Chan C, Li Z, Zhou Q (May 2012). "The ubiquitin ligase Siah1 controls ELL2 stability and formation of super elongation complexes to modulate gene transcription". Mol. Cell. 46 (3): 325–34. doi:10.1016/j.molcel.2012.03.007. PMC 3360964. PMID 22483617.
- Mann MC, Strobel S, Fleckenstein B, Kress AK (September 2014). "The transcription elongation factor ELL2 is specifically upregulated in HTLV-1-infected T-cells and is dependent on the viral oncoprotein Tax". Virology. 464–465: 98–110. doi:10.1016/j.virol.2014.06.028. PMID 25058508.
- Park KS, Bayles I, Szlachta-McGinn A, Paul J, Boiko J, Santos P, Liu J, Wang Z, Borghesi L, Milcarek C (November 2014). "Transcription elongation factor ELL2 drives Ig secretory-specific mRNA production and the unfolded protein response". J. Immunol. 193 (9): 4663–74. doi:10.4049/jimmunol.1401608. PMC 4201982. PMID 25238757.
- Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson BM, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, Lenhoff S, Masson G, Mellqvist UH, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, Nahi H, Gudbjartsson DF, Rafnar T, Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B (May 2015). "Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma". Nat Commun. 6: 7213. Bibcode:2015NatCo...6.7213S. doi:10.1038/ncomms8213. PMC 4455110. PMID 26007630.
- Huang Q, Zhang XW, Ma YS, Lu GX, Xie RT, Yang HQ, Lv ZW, Zhong XM, Liu T, Huang SX, Fu D, Xie C (July 2017). "Up-regulated microRNA-299 corrected with poor prognosis of glioblastoma multiforme patients by targeting ELL2". Jpn. J. Clin. Oncol. 47 (7): 590–596. doi:10.1093/jjco/hyw188. PMID 28531325.
- Alexander LM, Watters J, Reusch JA, Maurin M, Nepon-Sixt BS, Vrzalikova K, Alexandrow MG, Murray PG, Wright KL (November 2017). "Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival". Mol. Immunol. 91: 8–16. doi:10.1016/j.molimm.2017.08.016. PMC 5653440. PMID 28858629.
- Pascal LE, Masoodi KZ, Liu J, Qiu X, Song Q, Wang Y, Zang Y, Yang T, Wang Y, Rigatti LH, Chandran U, Colli LM, Vencio RZ, Lu Y, Zhang J, Wang Z (November 2017). "Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia". J. Endocrinol. 235 (2): 123–136. doi:10.1530/JOE-17-0112. PMC 5679084. PMID 28870994.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.